Genprex, Inc. Granted Nasdaq Exception to Regain $1.00 Bid-Price Compliance

What Happened

• Genprex, Inc. (GNPX) filed an 8‑K reporting that a Nasdaq Hearings Panel granted the company an exception to demonstrate compliance with Nasdaq’s $1.00 minimum bid-price requirement. The Panel hearing was held July 21, 2026, and the exception was granted on July 29, 2026.
• Under the exception, Genprex needed to demonstrate compliance on or before July 29, 2026 and then maintain a closing bid price of at least $1.00 per share on each trading day through December 7, 2026, when the Panel’s jurisdiction in this matter ends. The Panel may impose a discretionary Panel Monitor and reserves the right to reconsider the exception if new adverse events arise.

Key Details

• Nasdaq originally notified Genprex on June 10, 2026 that it intended to delist the company for failing to meet Listing Rule 5550(a)(2) (minimum $1.00 bid price) unless Genprex requested a hearing.
• Panel timeline and conditions: hearing July 21, 2026; exception granted July 29, 2026; must maintain ≥ $1.00 closing bid daily through Dec 7, 2026.
• Genprex implemented a 1-for-22 reverse stock split effective July 16, 2026 to help meet the bid price requirement.
• Other listing requirements remain relevant (e.g., minimum stockholders’ equity of $2.5 million). Nasdaq rule changes effective July 22, 2026 can trigger immediate suspension/delisting if market value of listed securities falls below $5 million for 30 consecutive business days.

Why It Matters

• The Panel’s exception gives Genprex a temporary path to keep its Nasdaq listing, but it is conditional and time-limited. If Genprex fails to meet the terms, its shares could be delisted.
• Delisting would likely reduce liquidity, make trading and price discovery harder, and could materially impair the company’s ability to raise capital or maintain business relationships. The company has warned that the reverse stock split may not ensure sustained compliance or restore liquidity.
• Investors should watch the company’s closing share price daily, any updates on compliance or Panel actions, and disclosures about capital, stockholders’ equity and other listing qualifications.